Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Trials
Published in: Trials 1/2016

Open Access 01-12-2016 | Study protocol

Chinese herbal medicine Tangshen Formula treatment of patients with type 2 diabetic kidney disease with macroalbuminuria: study protocol for a randomized controlled trial

Authors: Meihua Yan, Yumin Wen, Liping Yang, Xi’ai Wu, Xiaoguang Lu, Bingxuan Zhang, Weiping Huang, Ping Li

Published in: Trials | Issue 1/2016

Login to get access

Abstract

Background

Diabetic kidney disease (DKD) is one of the most common microvascular complications of diabetes mellitus and the main cause of end-stage renal disease. Present medications for DKD are not entirely satisfactory. Preliminary studies indicate that the Chinese herbal formula Tangshen Formula (TSF) appears to decrease the proteinuria and improve the estimated glomerular filtration rate (eGFR) in DKD patients.

Methods/design

This trial is a five-center, randomized, double-blind, placebo-controlled study. DKD patients with a 24-h urinary protein (24 h UP) level between 0.5 and 3.5 g and serum creatinine < 265 μmol/L (3 mg/dl) will be included. A sample size of 144 participants will be randomly distributed into the treatment group (TSF plus irbesartan) and the control group (placebo plus irbesartan) at a ratio of 1:1. The study duration will be 50 weeks, comprising a 2-week run-in period, 24 weeks of intervention, and 24 weeks of follow-up. The primary endpoint will be the 24 h UP. Secondary endpoints will be an evaluation of renal function, management of blood lipids, improvement in traditional Chinese medicine symptoms, and safety assessments. Adverse events will also be evaluated.

Discussion

This study will provide evidence for the effectiveness and safety of TSF compared to placebo in treating DKD patients with macroalbuminuria.

Trial registration

Chinese Clinical Trials Registry, ChiCTR-TRC-13003566. Registered 9 August 2013.
Appendix
Available only for authorised users
Literature
1.
2.
Ruggenenti P, Remuzzi G. Nephropathy of type 1 and type 2 diabetes: diverse pathophysiology, same treatment? Nephrol Dial Transplant. 2000;15(12):1900–2.CrossRefPubMed
3.
American Diabetes Association. 9. Microvascular complications and foot care. Diabetes Care. 2016;39 Suppl 1:S72–80. doi:10.​2337/​dc16-S012.
4.
Cheng X, Nayyar S, Wang M, Li X, Sun Y, Huang W, et al. Mortality rates among prevalent hemodialysis patients in Beijing: a comparison with USRDS data. Nephrol Dial Transplant. 2013;28(3):724–32. doi:10.​1093/​ndt/​gfs326.CrossRefPubMed
5.
6.
7.
8.
9.
10.
11.
Zhao XF, Su SJ, Yun G, Guo YH, Wang S. Mortality and recurrence of vascular disease among stroke patients treated with combined TCM therapy. J Tradit Chin Med. 2012;32(2):173–8.CrossRefPubMed
12.
13.
Chen G, Wu X, Yang L, Yang X, Yan M, Li P. Using the Delphi method to survey clinical experts on the characteristics of traditional Chinese symptoms of diabetic nephropathy. China J Trad Chin Med Pharm. 2011;26:2241–4. Chinese.
14.
Yang S, Wang Y, Chen Z, Lv J, Wang X, Hu C, et al. Common Chinese medicine syndromes of diabetic nephropathy questionnaire-based study of experts. Chin J Integr Trad West Nephrol. 2013;14:1097–9. Chinese.
15.
Zhou D, Zhao J, Mou X, Liu W, Zhou D, Liu Y, et al. Distribution of syndrome stages of diabetic nephropathy. J Beijing Univ Tradit Chin Medi Chin Med Clin Edition. 2012;19(1):38–41. Chinese.
16.
Yang L, Li P, Du J, Li J, Deng D, Zhan Y. Canonical correlation analysis of traditional Chinese syndrome and laboratory parameters in 350 patients with diabetic nephropathy. China J Tradit Chin Med Pharm. 2010;25:686–9. Chinese.
17.
Zhang H, Li P, Burczynski FJ, Gong Y, Choy P, Sha H, et al. Attenuation of diabetic nephropathy in Otsuka Long-Evans Tokushima Fatty (OLETF) rats with a combination of Chinese herbs (Tangshen Formula). Evid Based Complement Alternat Med. 2011;2011:613737. doi:10.​1155/​2011/​613737.PubMedPubMedCentral
18.
Zhang H, Li P, Zhao J, Zhao S, Yan M, Luo Y. Effect of Tangshen Formula on expression of TGF-β1 and MMP-9 of renal tissue in STZ-induced diabetic nephropathy rats. Chin J Integr Trad West Nephrol. 2009;10:290–4. Chinese.
19.
Guo J, Li P, Wan F, Zhao T, Dong X, Li X, et al. Protective effect of Tangshen Formula on renal function and IL-10, TNF-α, and DA in OLETF rats. Chin J Integr Trad West Nephrol. 2011;12(12):1044–7.
20.
Zhu C, Huang M, Liang Q, Wang Y, Hu P, Li P, et al. Effects of Tangshen Formula on phospholipids metabolism in spontaneous Type 2 Diabetic rats. Chem J Chin Univ. 2011;32(7):1512–8. Chinese.
21.
22.
23.
24.
Zheng X. Clinical research guideline of new investigational drug in traditional Chinese medicine. Beijing: China Medical Science Press; 2002.
25.
Levey AS, Stevens LA, Schmid CH, Zhang YL. Castro 3rd AF, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604–12.CrossRefPubMedPubMedCentral
26.
27.
Danan G, Benichou C. Causality assessment of adverse reactions to drugs--I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol. 1993;46(11):1323–30.CrossRefPubMed
28.
29.
World Health Organization. World Health Organization Collaborating Centre for International Drug Monitoring; Uppsala Monitoring Centre. http://​www.​who-umc.​org. Accessed 26 Apr 2016.
30.
31.
Gagnier JJ, Boon H, Rochon P, Moher D, Barnes J, Bombardier C, et al. Reporting randomized, controlled trials of herbal interventions: an elaborated CONSORT statement. Ann Intern Med. 2006;144(5):364–7.CrossRefPubMed
Metadata
Title
Chinese herbal medicine Tangshen Formula treatment of patients with type 2 diabetic kidney disease with macroalbuminuria: study protocol for a randomized controlled trial
Authors
Meihua Yan
Yumin Wen
Liping Yang
Xi’ai Wu
Xiaoguang Lu
Bingxuan Zhang
Weiping Huang
Ping Li
Publication date
01-12-2016
Publisher
BioMed Central
Published in
Trials / Issue 1/2016
Electronic ISSN: 1745-6215
DOI
https://doi.org/10.1186/s13063-016-1385-2

Other articles of this Issue 1/2016

Trials 1/2016 Go to the issue

Study protocol

Efficacy, safety, and tolerability of lacosamide in patients with gain-of-function Nav1.7 mutation-related small fiber neuropathy: study protocol of a randomized controlled trial–the LENSS study

Study protocol

A telemedicine meditation intervention for people with multiple sclerosis and their caregivers: study protocol for a randomized controlled trial

Study protocol

A complex behavioural change intervention to reduce the risk of diabetes and prediabetes in the pre-conception period in Malaysia: study protocol for a randomised controlled trial

Study protocol

Evaluation of low-level laser at auriculotherapy points to reduce postoperative pain in inferior third molar surgery: study protocol for a randomized controlled trial

Study protocol

The effect of community groups and mobile phone messages on the prevention and control of diabetes in rural Bangladesh: study protocol for a three-arm cluster randomised controlled trial

Study protocol

Working memory and processing speed training in schizophrenia: study protocol for a randomized controlled trial